Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Requires rigorous navigation between laboratory, clinic, and society
| The first 150 words of the full text of this article appear below. |
Advances in molecular genetics over the past decade have been remarkable. Soon the entire human genome will have been sequenced and most of the genetic loci associated with human disease identified. These advances have greatly enhanced understanding of disease mechanisms and begun to explain why the clinical course of common disorders such as diabetes, asthma, and rheumatoid arthritis is so variable, as Bell discusses in the first of four articles on the broader implications of the new genetics (p 618).1 In future presymptomatic population based genetic testing for common late onset disorders such as Alzheimer's disease2 and colon cancer may become widespread and bring important health benefits. Genotyping may become part of routine investigations to help clinicians tailor drug treatment effectively.
But in what has been dubbed the "post-genome" era, increasing
attention is now being paid to the limitations as well as the potential
of DNA based genetic tests. The